Medpace Holdings Toekomstige groei
Future criteriumcontroles 3/6
Medpace Holdings zal naar verwachting groeien in winst en omzet met respectievelijk 10.9% en 10% per jaar. De winst per aandeel zal naar verwachting groeien met 10.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 26.6% zijn.
Belangrijke informatie
10.9%
Groei van de winst
10.3%
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.3% |
| Inkomstengroei | 10.0% |
| Toekomstig rendement op eigen vermogen | 26.6% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 23 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Why Medpace Holdings Is A 'Better Mousetrap'
Oct 16Medpace Holdings, Inc.'s (NASDAQ:MEDP) Earnings Haven't Escaped The Attention Of Investors
Sep 19
Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Sep 02Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem
Jul 31Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jul 25What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E
Jun 18Medpace: Clear Winner If China Blockade Succeeds
Jun 04A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
May 22Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?
Apr 12Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors
Feb 18Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Feb 09A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jan 25Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Jan 10Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price
Dec 26Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?
Nov 08Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate
Oct 23If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity
Oct 10Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Aug 27Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 31A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jul 18Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Jul 04Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?
May 25Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Apr 27An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued
Apr 12We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease
Mar 27Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Feb 14What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?
Jan 16Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate
Jan 03Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Dec 20Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet
Nov 16Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%
Nov 03Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,597 | 464 | 564 | 599 | 10 |
| 12/31/2025 | 2,290 | 406 | 479 | 514 | 11 |
| 12/31/2024 | 2,108 | 381 | 472 | 510 | 8 |
| 9/30/2024 | 2,071 | 366 | 536 | 575 | N/A |
| 6/30/2024 | 2,030 | 340 | 503 | 540 | N/A |
| 3/31/2024 | 1,963 | 312 | 473 | 506 | N/A |
| 12/31/2023 | 1,886 | 283 | 397 | 433 | N/A |
| 9/30/2023 | 1,782 | 273 | 378 | 414 | N/A |
| 6/30/2023 | 1,673 | 268 | 373 | 408 | N/A |
| 3/31/2023 | 1,563 | 257 | 385 | 422 | N/A |
| 12/31/2022 | 1,460 | 245 | 351 | 388 | N/A |
| 9/30/2022 | 1,374 | 227 | 286 | 322 | N/A |
| 6/30/2022 | 1,286 | 209 | 250 | 286 | N/A |
| 3/31/2022 | 1,213 | 199 | 221 | 252 | N/A |
| 12/31/2021 | 1,142 | 181 | 235 | 263 | N/A |
| 9/30/2021 | 1,094 | 182 | 271 | 298 | N/A |
| 6/30/2021 | 1,028 | 175 | 256 | 285 | N/A |
| 3/31/2021 | 955 | 159 | 235 | 267 | N/A |
| 12/31/2020 | 926 | 145 | 227 | 259 | N/A |
| 9/30/2020 | 896 | 124 | 181 | 210 | N/A |
| 6/30/2020 | 882 | 107 | 188 | 215 | N/A |
| 3/31/2020 | 891 | 110 | 196 | 217 | N/A |
| 12/31/2019 | 861 | 100 | 184 | 202 | N/A |
| 9/30/2019 | 823 | 93 | 169 | 184 | N/A |
| 6/30/2019 | 786 | 88 | 160 | 173 | N/A |
| 3/31/2019 | 742 | 78 | 153 | 167 | N/A |
| 12/31/2018 | 705 | 73 | 141 | 157 | N/A |
| 9/30/2018 | 612 | 61 | 130 | 146 | N/A |
| 6/30/2018 | 531 | 52 | N/A | 132 | N/A |
| 3/31/2018 | 456 | 45 | N/A | 121 | N/A |
| 12/31/2017 | 386 | 39 | N/A | 97 | N/A |
| 9/30/2017 | 382 | 28 | N/A | 98 | N/A |
| 6/30/2017 | 379 | 23 | N/A | 101 | N/A |
| 3/31/2017 | 377 | 18 | N/A | 78 | N/A |
| 12/31/2016 | 371 | 13 | N/A | 92 | N/A |
| 9/30/2016 | 361 | 5 | N/A | 91 | N/A |
| 6/30/2016 | 348 | 0 | N/A | 80 | N/A |
| 3/31/2016 | 332 | -5 | N/A | 94 | N/A |
| 12/31/2015 | 320 | -9 | N/A | 86 | N/A |
| 12/31/2014 | 290 | -16 | N/A | 75 | N/A |
| 12/31/2013 | 244 | 25 | N/A | 98 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei MEDP ( 10.9% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van MEDP ( 10.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van MEDP zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van MEDP ( 10% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van MEDP ( 10% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen MEDP zal naar verwachting over 3 jaar hoog zijn ( 26.6 %)